

## DAFTAR PUSTAKA

- Abeloff, M. D., Armitage, J. O., Niederhuber, J. E., Kastan, M. B., & McKenna, W. G. (2020). *Abeloff's Clinical Oncology E-Book*. Elsevier Health Sciences.
- Ahmad, F. H. (2021). *Hubungan Subtipe Kanker Payudara dengan Kejadian Metastasis di RSUP Dr. M. Djamil Padang (Doctoral dissertation, Universitas Andalas)*.
- Akram, M., Iqbal, M., Daniyal, M., & Khan, A. U. (2017). Awareness and current knowledge of breast cancer. *Biological research*, 50(1), 1-23.
- American Cancer Society. *Breast Cancer Facts & Figures 2019-2020*. Atlanta: American Cancer Society, Inc. 2019.
- Anwar, S. L., Tampubolon, G., Van Hemelrijck, M., Hutajulu, S. H., Watkins, J., & Wulaningsih, W. (2018). Determinants of cancer screening awareness and participation among Indonesian women. *BMC cancer*, 18(1), 1-11.
- Ayubi, C. M. S. H. A., Hasan, A. H., & Damayanti, M. M. (2020). *Karakteristik Penderita Kanker Payudara Berdasarkan Usia, Riwayat Menopause dan Gambaran Histopatologi di RSUD Al-Ihsan Periode Agustus–November 2019*.
- Azhar, Y., Agustina, H., Abdurahman, M., & Achmad, D. (2020). Breast cancer in west java: where do we stand and go?. *Indonesian Journal of Cancer*, 14(3), 91-96.
- Barton, H., Shatti, D., Jones, C. A., Sakthithasan, M., & Loughborough, W. W. (2018). Review of radiological screening programmes for breast, lung and pancreatic malignancy. *Quantitative imaging in medicine and surgery*, 8(5),

525.

Bevers, T. B., Helvie, M., Bonaccio, E., Calhoun, K. E., Daly, M. B., Farrar, W. B., ... & Kumar, R. (2018). Breast cancer screening and diagnosis, version 3.2018, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network*, 16(11), 1362-1389.

Breastcancer.org, What is breast cancer ? [laman di internet] [diperbarui pada 18 Mei 2018; diakses pada tanggal 21 April 2021]. Diakses dari [http://www.breastcancer.org/symptoms/understand\\_bc/what\\_is\\_bc](http://www.breastcancer.org/symptoms/understand_bc/what_is_bc)

Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., ... & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*, 30(8), 1194-1220.

Cdc.gov, what is breast cancer? [laman di internet] [diperbarui pada 14 September 2020; diakses pada tanggal 15 April 2021]. Diakses dari [https://www.cdc.gov/cancer/breast/basic\\_info/what-is-breast-cancer.htm](https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm)

Chaitanya, I. N. V. L., Prabhala, S., Annapurna, S., & Deshpande, A. K. (2020). Comparison of Histopathologic Findings with BIRADS Score in Trucut Biopsies of Breast Lesions. *Call for Editorial Board Members*, 9(1 Part I), 35.

Chen, M. T., Sun, H. F., Zhao, Y., Fu, W. Y., Yang, L. P., Gao, S. P., ... & Jin, W. (2017). Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population-based analysis. *Scientific reports*, 7(1), 1-8.

Cheng, Q., Huang, J., Liang, J., Ma, M., Ye, K., Shi, C., & Luo, L. (2020). The

diagnostic performance of DCE-MRI in evaluating the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. *Frontiers in oncology*, 10, 93.

de Almeida, J., Gomes, A. B., Barros, T. P., Fahel, P. E., & Rocha, M. S. (2017).

Diffusion-weighted imaging of suspicious (BI-RADS 4) breast lesions: stratification based on histopathology. *Radiologia brasileira*, 50(3), 154–161. <https://doi.org/10.1590/0100-3984.2015.0224>

Fischer, U., Baum, F., & Luftner-Nagel, S. (2018). *Breast cancer: Diagnostic imaging and therapeutic guidance*. Thieme.

Giuliano, A. E., Edge, S. B., & Hortobagyi, G. N. (2018). of the AJCC cancer staging manual: breast cancer. *Annals of surgical oncology*, 25(7), 1783-1785.

Hasbie, N. F., Mandala, Z., Wiratmoko, W., & Husain, B. M. A. (2020).

Perbandingan Tingkat Validitas Pemeriksaan Mammografi dan USG untuk Mendiagnosis Neoplasma Mammae di Rumah Sakit Umum Daerah Dr. H. Abdul Moeloek Tahun 2017-2018. *Jurnal Ilmu Kedokteran dan Kesehatan*, 7(2).

Karim, M. O., Khan, K. A., Khan, A. J., Javed, A., Fazid, S., & Aslam, M. I. (2020).

Triple Assessment of Breast Lump: Should We Perform Core Biopsy for Every Patient?. *Cureus*, 12(3).

Khattak, M. S., Ahmad, F., & Rehman, K. U. (2020). Role of fine needle

aspiration cytology in diagnosis of palpable breast lesions and their comparison with histopathology. *Journal of Ayub Medical College Abbottabad*, 32(1), 83-86.

- Koo, M. M., von Wagner, C., Abel, G. A., McPhail, S., Rubin, G. P., & Lyratzopoulos, G. (2017). Typical and atypical presenting symptoms of breast cancer and their associations with diagnostic intervals: Evidence from a national audit of cancer diagnosis. *Cancer epidemiology*, 48, 140-146.
- Kutluer, N., Aksu, A., Bozan, M. B., Kanat, B. H., Kargici, H., Cay, F., & Bozan, A. A. (2019). Correlation between histopathological results and BI-RADS classification in breast masses. *Annals of Medical Research*, 26(11), 2698-2701.
- Mardiah, H., Ginting, R. N. A., Rahmadhany, H., & Sitorus, E. R. D. (2021). Correlation between Age and Body Mass Index (BMI) with Histopathological Features of Breast Cancer Patients in RSUP Haji Adam Malik Medan. *Indonesian Journal of Cancer*, 15(2), 46-53.
- Michaels, A., Chung, C. S., Birdwell, R. L., Frost, E. P., & Giess, C. S. (2017). Imaging and Histopathologic Features of BI-RADS 3 Lesions Upgraded during Imaging Surveillance. *The breast journal*, 23(1), 10–16. <https://doi.org/10.1111/tbj.12677>
- Obrzut, M., Cholewa, M., Baran, J., Obrzut-Palusińska, A., & Kurczab, E. (2018). Does fine-needle aspiration biopsy still have a place in the diagnosis of breast lesions?. *Przegląd menopauzalny= Menopause review*, 17(1), 28.
- Partini, P. D. O., Nirvana, I. W., & Adiputra, P. A. T. (2018). Karakteristik kanker payudara usia muda di Subbagian Bedah Onkologi Rumah Sakit Umum Pusat Sanglah tahun 2014-2016. *Intisari Sains Medis*, 9(1), 76-79.
- Piaseczny, M. M., & Allan, A. L. (2014). Why does breast cancer often spread to

- the lung?. *Women's Health*, 10(6), 561-564.
- Siregar, Y. (2017). Karakteristik dan Gambaran Klinis Penderita Kanker Payudara di RSUP Haji Adam Malik Medan Periode Januari–Juni Tahun 2017.
- Sood, R., Rositch, A. F., Shakoor, D., Ambinder, E., Pool, K. L., Pollack, E., ... & Harvey, S. C. (2019). Ultrasound for breast cancer detection globally: a systematic review and meta-analysis. *Journal of global oncology*, 5, 1-17.
- Sun, Y. S., Zhao, Z., Yang, Z. N., Xu, F., Lu, H. J., Zhu, Z. Y., ... & Zhu, H. P. (2017). Risk factors and preventions of breast cancer. *International journal of biological sciences*, 13(11), 1387.
- Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer Clin*. 2021; 71: 209- 249. <https://doi.org/10.3322/caac.21660>
- Townsend, C. M., Beauchamp, R. D., Evers, B. M., & Mattox, K. L. (2017). *Sabiston textbook of surgery E-book*. Elsevier Health Sciences.
- Uicc.org, breast cancer [laman di internet] [diperbarui pada 19 Maret 2021; diakses pada tanggal 10 April 2021]. Diakses dari <https://www.uicc.org/what-we-do/thematic-areas-work/breast-cancer>
- Walker, S., Hyde, C., & Hamilton, W. (2014). Risk of breast cancer in symptomatic women in primary care: a case–control study using electronic records. *British Journal of General Practice*, 64(629), e788-e793.
- Wang, H., Zhang, C., Zhang, J., Kong, L., Zhu, H., & Yu, J. (2017). The

prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study. *Oncotarget*, 8(16), 26368–26379. <https://doi.org/10.18632/oncotarget.14300>

Wang, L. (2017). Early diagnosis of breast cancer. *Sensors*, 17(7), 1572.

Wu, S. G., Li, H., Tang, L. Y., Sun, J. Y., Zhang, W. W., Li, F. Y., ... & He, Z. Y. (2017). The effect of distant metastases sites on survival in de novo stage-IV breast cancer: A SEER database analysis. *Tumor Biology*, 39(6), 1010428317705082.

Wu, Q., Li, J., Zhu, S., Wu, J., Chen, C., Liu, Q., Wei, W., Zhang, Y., & Sun, S. (2017). Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. *Oncotarget*, 8(17), 27990–27996. <https://doi.org/10.18632/oncotarget.15856>

Youn, H. J., & Han, W. (2020). A review of the epidemiology of breast cancer in Asia: focus on risk factors. *Asian Pacific journal of cancer prevention: APJCP*, 21(4), 867.

## LAMPIRAN

### Lampiran 1 : Biodata Diri Penulis



Nama : Nurul Amalina Khairuddin  
Stambuk : C011181509  
TTL : Makassar, 12 Juli 2000  
Agama : Islam  
Suku : Makassar  
Alamat : Jl. Hertasning IX Blok E17 No. 12  
Nama Ayah : Khairuddin Djawad  
Nama Ibu : Suciyanti Sahabu  
Alamat Orang Tua : Jl. Hertasning IX Blok E17 No. 12  
Anak Ke : 3 dari 3 bersaudara  
No.telpon : 081342131131  
Email : nurulamalinak@gmail.com

### **Riwayat pendidikan**

<b>Periode</b>	<b>Sekolah/Institusi/Universitas</b>	<b>Jurusan</b>
2012	SD Islam Athirah 1 Makassar	
2015	SMP Islam Athirah 1 Makassar	
2018	SMA Negeri 17 Makassar	IPA
2018- Sekarang	Fakultas Kedokteran Universitas Hasanuddin	Pendidikan Dokter Umum

### **Riwayat Organisasi**

<b>Periode</b>	<b>Sekolah/Institusi/Universitas</b>	<b>Jabatan</b>
2019 - Sekarang	Medical Youth Research Club FK UNHAS	Anggota



**Lampiran 2. Tabel Data Penelitian RSUP Dr. Wahidin Sudirohusodo**

NO	RM	JK	USIA	GEJALA KLINIS	STADIUM	METASTASIS	USG	PA
1	878140	P	44	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
2	840800	P	43	BENJOLAN PAYUDARA BILATERAL	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
3	893030	P	41	BENJOLAN PAYUDARA KANAN	IIIB			INVASIF CARCINOMA MAMMAE
4	879920	P	63	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IIIB		BI-RADS 5	INVASIF CARCINOMA MAMMAE
5	870120	P	44	BENJOLAN PAYUDARA KANAN	II			INVASIF CARCINOMA MAMMAE
6	883360	P	58	BENJOLAN PAYUDARA KIRI	IIIB			INVASIF CARCINOMA MAMMAE
7	886020	P	39	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU, TULANG		INVASIF CARCINOMA MAMMAE
8	890420	P	40	BENJOLAN PAYUDARA KANAN	IV	OTAK		INVASIF CARCINOMA MAMMAE
9	890570	P	53	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU, TULANG		INVASIF CARCINOMA MAMMAE
10	881290	P	45	BENJOLAN PAYUDARA KANAN	IIIB			INVASIF CARCINOMA MAMMAE
11	890190	P	45	BENJOLAN PAYUDARA KANAN	IV	TULANG, HEPAR		INVASIF CARCINOMA MAMMAE
12	893410	P	53	BENJOLAN PAYUDARA KANAN	IIIB			INVASIF CARCINOMA MAMMAE
13	900860	P	65	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
14	900500	P	29	BENJOLAN PAYUDARA KIRI	IIIB			INVASIF CARCINOMA MAMMAE
15	902210	P	38	BENJOLAN PAYUDARA KIRI	IIIB			INVASIF CARCINOMA MAMMAE
16	904120	P	47	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE
17	907210	P	64	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
18	908170	P	50	BENJOLAN PAYUDARA KANAN	IV	HEPAR		INVASIF CARCINOMA MAMMAE

19	907450	P	39	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IIIC			INVASIF CARCINOMA MAMMAE
20	893740	P	47	BENJOLAN PAYUDARA KIRI	II			INVASIF CARCINOMA MAMMAE
21	909400	P	35	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
22	240390	P	33	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU, OTAK		INVASIF CARCINOMA MAMMAE
23	909110	P	46	BENJOLAN PAYUDARA KANAN	IV	TULANG		INVASIF CARCINOMA MAMMAE
24	878700	P	43	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	txnxm0			INVASIF CARCINOMA MAMMAE
25	908170	P	38	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE
26	917050	P	32	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
27	893030	P	54	BENJOLAN PAYUDARA KIRI, PERDARAHAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
28	909480	P	62	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
29	907670	P	50	BENJOLAN PAYUDARA KANAN	IV	HEPAR		INVASIF CARCINOMA MAMMAE
30	922920	P	51	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE
31	693850	P	38	BENJOLAN PAYUDARA KANAN	IIIB			INVASIF CARCINOMA MAMMAE
32	925850	P	62	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
33	930530	P	37	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	txnxm0			INVASIF CARCINOMA MAMMAE
34	925960	P	69	BENJOLAN PAYUDARA KANAN	IV	HEPAR		INVASIF CARCINOMA MAMMAE
35	923710	P	54	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
36	866191	P	57	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE

37	881291	P	38	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
38	878911	P	63	BENJOLAN PAYUDARA KIRI, PERDARAHAN	txnxm0			INVASIF CARCINOMA MAMMAE
39	895551	P	50	BENJOLAN PAYUDARA KIRI	IV	TULANG		INVASIF CARCINOMA MAMMAE
40	906761	P	47	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
41	205581	P	53	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE
42	866191	P	60	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
43	867601	P	46	BENJOLAN PAYUDARA KANAN	txn0m0			INVASIF CARCINOMA MAMMAE
44	885911	P	55	BENJOLAN PAYUDARA KIRI	IIIA			INVASIF CARCINOMA MAMMAE
45	887561	P	44	BENJOLAN PAYUDARA KANAN	IV	HEPAR		INVASIF CARCINOMA MAMMAE
46	890631	P	55	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
47	880871	P	59	BENJOLAN PAYUDARA KANAN	IIIB		BI-RADS 4	INVASIF CARCINOMA MAMMAE
48	895681	P	53	BENJOLAN PAYUDARA KANAN	IIIB			INVASIF CARCINOMA MAMMAE
49	895391	P	52	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU, TULANG		INVASIF CARCINOMA MAMMAE
50	900821	P	69	BENJOLAN PAYUDARA KANAN	IV	OTAK		INVASIF CARCINOMA MAMMAE
51	899481	P	59	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IV	TULANG, HEPAR		INVASIF CARCINOMA MAMMAE
52	898111	P	55	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IV	TULANG		INVASIF CARCINOMA MAMMAE
53	905341	P	65	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE

54	892311	P	38	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU, HEPAR		INVASIF CARCINOMA MAMMAE
55	904991	P	49	BENJOLAN PAYUDARA KIRI	IIIB			INVASIF CARCINOMA MAMMAE
56	844501	P	52	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
57	205581	P	53	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	III		BI-RADS 4	INVASIF CARCINOMA MAMMAE
58	909211	P	52	BENJOLAN PAYUDARA KIRI	IIB			INVASIF CARCINOMA MAMMAE
59	915511	P	56	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	txnxm0			INVASIF CARCINOMA MAMMAE
60	912291	P	53	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU, TULANG		INVASIF CARCINOMA MAMMAE
61	919041	P	51	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IV	HEPAR		INVASIF CARCINOMA MAMMAE
62	918111	P	42	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
63	888091	P	45	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU, TULANG		INVASIF CARCINOMA MAMMAE
64	888101	P	48	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IIIC			INVASIF CARCINOMA MAMMAE
65	899341	P	50	BENJOLAN PAYUDARA KANAN	IIIA			INVASIF CARCINOMA MAMMAE
66	909651	P	54	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
67	910271	P	57	BENJOLAN PAYUDARA KIRI	IV	OTAK		INVASIF CARCINOMA MAMMAE
68	838701	P	64	BENJOLAN PAYUDARA KANAN	TxN0M0			INVASIF CARCINOMA MAMMAE
69	931991	P	48	BENJOLAN PAYUDARA BILATERAL, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE
70	932871	P	52	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE

71	925611	P	51	BENJOLAN PAYUDARA KIRI	IIB			INVASIF CARCINOMA MAMMAE
72	924761	P	48	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
73	920341	P	53	BENJOLAN PAYUDARA KIRI	IIIB		BI-RADS 5	INVASIF CARCINOMA MAMMAE
74	931571	P	45	BENJOLAN PAYUDARA KANAN	IV	HEPAR		INVASIF CARCINOMA MAMMAE
75	925341	P	47	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IV	TULANG		INVASIF CARCINOMA MAMMAE
76	883812	P	50	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IV	TULANG		INVASIF CARCINOMA MAMMAE
77	899352	P	47	BENJOLAN PAYUDARA KANAN	txn1m0			INVASIF CARCINOMA MAMMAE
78	912322	P	47	BENJOLAN PAYUDARA KANAN	IV	TULANG		INVASIF CARCINOMA MAMMAE
79	881162	P	42	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
80	878242	P	36	BENJOLAN PAYUDARA KANAN, PERDARAHAN	txnxm0			INVASIF CARCINOMA MAMMAE
81	890792	P	44	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
82	885602	P	45	BENJOLAN PAYUDARA KANAN	IIIA		BI-RADS 4	INVASIF CARCINOMA MAMMAE
83	879672	P	67	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IV	OTAK		INVASIF CARCINOMA MAMMAE
84	903932	P	42	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
85	900652	P	62	BENJOLAN PAYUDARA KANAN	IIIB		BI-RADS 4	INVASIF CARCINOMA MAMMAE
86	883522	P	44	BENJOLAN PAYUDARA KIRI	IIIC			INVASIF CARCINOMA MAMMAE
87	882653	P	51	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	txnxm0			INVASIF CARCINOMA MAMMAE

88	894415	P	51	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	txnxm0			INVASIF CARCINOMA MAMMAE
89	895125	P	32	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE
90	889062	P	41	BENJOLAN PAYUDARA BILATERAL	IV	PARU-PARU, HEPAR		INVASIF CARCINOMA MAMMAE

**Lampiran 3. Tabel Data Penelitian RSP Universitas Hasanuddin**

NO	RM	JK	USIA	GEJALA KLINIS	STADIUM	METASTASIS	USG	PA
1	110223	P	45	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
2	143317	P	53	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
3	145875	P	65	BENJOLAN PAYUDARA KANAN, PEAU D'ORANGE, RETRAKSI	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
4	149143	P	43	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
5	147196	P	60	BENJOLAN PAYUDARA KIRI , PEAU D'ORANGE	IIB			INVASIF CARCINOMA MAMMAE
6	147105	P	50	BENJOLAN PAYUDARA KIRI	IIIC		BI-RADS 5	INVASIF CARCINOMA MAMMAE
7	152272	P	46	BENJOLAN PAYUDARA KIRI	IIIB			INVASIF CARCINOMA MAMMAE
8	8902	P	76	BENJOLAN PAYUDARA KANAN	IA			INVASIF CARCINOMA MAMMAE
9	13971	P	51	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
10	30190	P	63	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU, TULANG		INVASIF CARCINOMA MAMMAE
11	38985	P	64	BENJOLAN PAYUDARA KANAN	txnxm0		BI-RADS 3	INVASIF CARCINOMA MAMMAE
12	44366	P	43	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE

13	47917	P	43	BENJOLAN PAYUDARA KANAN	IV	TULANG		INVASIF CARCINOMA MAMMAE
14	48520	P	37	BENJOLAN PAYUDARA BILATERAL	IV	TULANG		INVASIF CARCINOMA MAMMAE
15	54354	P	60	BENJOLAN PAYUDARA KIRI	txnxm0		BI-RADS 4	INVASIF CARCINOMA MAMMAE
16	84136	P	53	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
17	85827	P	56	BENJOLAN PAYUDARA KIRI	txnxm0		BI-RADS 4	INVASIF CARCINOMA MAMMAE
18	92473	P	49	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
19	93224	P	54	BENJOLAN PAYUDARA KANAN	IV	TULANG		INVASIF CARCINOMA MAMMAE
20	95926	P	45	BENJOLAN PAYUDARA KIRI	IV	OTAK		INVASIF CARCINOMA MAMMAE
21	139568	P	60	BENJOLAN PAYUDARA KIRI , PEAU D'ORANGE	txnxm0		BI-RADS 4	INVASIF CARCINOMA MAMMAE
22	142683	P	46	BENJOLAN PAYUDARA KANAN	IIIB			INVASIF CARCINOMA MAMMAE
23	143101	P	55	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE
24	143317	P	53	BENJOLAN PAYUDARA KANAN	IIIB		BI-RADS 5	INVASIF CARCINOMA MAMMAE
25	143432	P	52	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU	BI-RADS 4	INVASIF CARCINOMA MAMMAE
26	143540	P	72	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE



27	143651	P	47	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
28	143828	P	41	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
29	144185	P	30	BENJOLAN PAYUDARA KANAN	txnxm0		BI-RADS 5	INVASIF CARCINOMA MAMMAE
30	144316	P	31	BENJOLAN PAYUDARA BILATERAL	txnxm0			INVASIF CARCINOMA MAMMAE
31	144839	P	62	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU, TULANG		INVASIF CARCINOMA MAMMAE
32	144882	P	54	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
33	144956	P	39	BENJOLAN PAYUDARA KANAN	IV			INVASIF CARCINOMA MAMMAE
34	145252	P	39	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
35	145307	P	38	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
36	145615	P	36	BENJOLAN PAYUDARA KIRI	IV	OTAK, PARU-PARU		INVASIF CARCINOMA MAMMAE
37	147105	P	50	BENJOLAN PAYUDARA KIRI	IIIC		BI-RADS 5	INVASIF CARCINOMA MAMMAE
38	147196	P	60	BENJOLAN PAYUDARA KIRI , PEAU D'ORANGE	IIIB			INVASIF CARCINOMA MAMMAE
39	148204	P	51	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
40	148306	P	60	BENJOLAN PAYUDARA KIRI , PEAU D'ORANGE	IIIB			INVASIF CARCINOMA MAMMAE

41	148430	P	67	BENJOLAN PAYUDARA KANAN	IIB			INVASIF CARCINOMA MAMMAE
42	149765	P	33	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
43	150252	P	38	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
44	150647	P	53	BENJOLAN PAYUDARA KANAN	IIIB		BI-RADS 4	INVASIF CARCINOMA MAMMAE
45	111044	P	46	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IIA			INVASIF CARCINOMA MAMMAE
46	111134	P	47	BENJOLAN PAYUDARA KANAN	IV	PARU-PARU		INVASIF CARCINOMA MAMMAE
47	111938	P	62	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IIIB	PARU-PARU, HEPAR		INVASIF CARCINOMA MAMMAE
48	113427	P	50	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	txnxmo			INVASIF CARCINOMA MAMMAE
49	113688	P	39	BENJOLAN PAYUDARA KIRI, NYERI, ULKUS	IIIB			INVASIF CARCINOMA MAMMAE
50	114327	P	60	BENJOLAN PAYUDARA KIRI	txnxm0		BI-RADS 4	INVASIF CARCINOMA MAMMAE
51	114504	P	40	BENJOLAN PAYUDARA KANAN, NYERI, ULKUS	txnxm0			INVASIF CARCINOMA MAMMAE
52	114585	P	37	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
53	114829	P	41	BENJOLAN PAYUDARA KIRI	IV	PARU-PARU, HEPAR, TULANG		INVASIF CARCINOMA MAMMAE
54	115025	P	45	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE

55	116398	P	47	BENJOLAN PAYUDARA KIRI	txnxm0		BI-RADS 3	INVASIF CARCINOMA MAMMAE
56	116761	P	47	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
57	117737	P	56	BENJOLAN PAYUDARA KANAN	txnxm0			INVASIF CARCINOMA MAMMAE
58	118206	P	54	BENJOLAN PAYUDARA KANAN	txnxm0		BI-RADS 4	INVASIF CARCINOMA MAMMAE
59	119945	P	45	BENJOLAN PAYUDARA BILATERAL, NYERI, ULKUS	txnxm0			INVASIF CARCINOMA MAMMAE
60	119990	P	46	BENJOLAN PAYUDARA KIRI	txnxm0			INVASIF CARCINOMA MAMMAE
61	119996	P	66	BENJOLAN PAYUDARA KANAN	txnxm0		BI-RADS 4	INVASIF CARCINOMA MAMMAE

## Lampiran 4. Rekomendasi Etik Penelitian



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
 KOMITE ETIK PENELITIAN KESEHATAN  
 RSPTN UNIVERSITAS HASANUDDIN  
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR  
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
 Contact Person: dr. Agussalim Bukhari.,M.Med.,Ph.D., SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



### **REKOMENDASI PERSETUJUAN ETIK**

Nomor : 514/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 18 Agustus 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21080485	No Sponsor Protokol	
Peneliti Utama	<b>Nurul Amalina Khairuddin</b>	Sponsor	
Judul Peneliti	Karakteristik Sosiodemografi dan Klinis Penderita Kanker Payudara di RSUP Dr Wahidin Sudirohusodo dan RSP Universitas Hasanuddin Tahun 2019-2021		
No Versi Protokol	<b>1</b>	Tanggal Versi	<b>16 Agustus 2021</b>
No Versi PSP		Tanggal Versi	
Tempat Penelitian	<b>RS Universitas Hasanuddin dan RS Dr. Wahidin Sudirohusodo Makassar</b>		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku <b>18 Agustus 2021</b> sampai <b>18 Agustus 2022</b>	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

## Lampran 5. Surat Izin Penelitian



### KEMENTERIAN KESEHATAN REPUBLIK INDONESIA

#### DIREKTORAT JENDERAL PELAYANAN KESEHATAN

RUMAH SAKIT UMUM PUSAT DR. WAHIDIN SUDIROHUSODO

Jalan Perintis Kemerdekaan Km. 11 Tamalanrea, Makassar, Kode Pos 90245

Telp. (0411) 584675 – 581818 (*Hunting*), Fax. (0411) 587676

Laman : [www.rsupwahidin.com](http://www.rsupwahidin.com) Surat Elektronik : [tu@rsupwahidin.com](mailto:tu@rsupwahidin.com)



Nomor : LB.02.01/2.2/1511/2021  
Hal : Izin Penelitian

07 September 2021

Yth. Kepala Instalasi Rekam Medik

Dengan ini kami hadapkan peneliti :

Nama : **Nurul Amalina Khairuddin**  
NIM : **C011181509**  
Prog. Studi : **Sarjana Kedokteran**  
Institusi : **Fakultas Kedokteran Univ. Hasanuddin Makassar**  
No. HP : **0813-4213-1131**

Yang bersangkutan akan melakukan penelitian dengan judul "**Karakteristik Sosiodemografi dan Klinis Penderita Kanker Payudara di RSUP Dr Wahidin Sudirohusodo dan RSP Universitas Hasanuddin Tahun 2019-2021**", sesuai surat dari Ketua PSSK FKUH, dengan Nomor **17092/UN4.6.8/PT.01.04/2021**, tertanggal **12 Agustus 2021**. Penelitian ini berlangsung sejak tanggal **07 September s.d 07 November 2021**, dengan catatan selama penelitian berlangsung peneliti:

1. Wajib memakai ID Card selama melakukan penelitian
2. Wajib mematuhi peraturan dan tata tertib yang berlaku
3. Tidak mengganggu proses pelayanan terhadap pasien
4. Tidak diperkenankan membawa status pasien keluar dari Ruang Rekam Medik
5. Tidak diperbolehkan mengambil gambar pasien dan identitas pasien harus dirahasiakan
6. Mematuhi protokol pencegahan Covid 19.

Setelah penelitian dilakukan, segera melaporkan Hasil Penelitian kepada Sub Bagian Penelitian dan Pengembangan untuk mendapatkan Surat Keterangan Selesai Meneliti.

Demikian, untuk di pergunakan sebagaimana mestinya.



Dr. Ridhayani B. SKM, M. Kes, Pendidikan dan Penelitian

Ridhayani B. SKM, M. Kes

NIP. 197010271997032001

